Talha Badar: TP53 mutation in Myeloproliferative neoplasms
Talha Badar shared on X: ,
“Genomic landscape, impact allelic burden, time to progression from CP-AP/BP in TP53 mutation MPN (Myeloproliferative neoplasms)—> AML (Acute Myeloid Leukemia).
TP53 mutation with VAF>40 had a poorer outcome.
No significant impact of the type of induction on the outcome.
Special thanks to Mobasher Kettani, Anand Patel, Rory M. Shallis, Jan Bewersdorf, Ehab Atallah, Aron Goldberg, Kashish Shah, Alex Coltoff.”
Source: Talha Badar/X
Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.
